SUBSCRIBE
SUBSCRIBE

Genentech, Inc.

NEWS
Drug Development
Genentech May Have a $5 Billion MS Blockbuster on Its Hands
September 29, 2015
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech’s ORATORIO Trial Meets Primary Endpoint in Phase III; FDA Data Submission Planned for 2016
September 28, 2015
 · 
3 min read
Biotech Bay
Genentech Shuttle Drivers Get Wage Increase
September 28, 2015
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech to Present Data from 15 Oncology Studies at European Cancer Congress
September 8, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech’s Hemophilia A Drug Gets Breakthrough Designation in Potential $11 Billion Market
September 4, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Joining the Anti-PD-L1 Cancer Drug Market, Syndax Inks Deal With Genentech, Closes on $80 Million Series C Round
August 26, 2015
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Constellation Pharma Mulls IPO After Genentech Declines to Buy
August 25, 2015
 · 
2 min read
Business
AstraZeneca PLC Taps Genentech’s Sean Bohen as New Chief Medial Officer
August 24, 2015
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Genentech’s Atezolizumab Shrank Tumors in Phase II Lung Cancer Trial
August 17, 2015
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Drug Development
FDA Grants Breakthrough Therapy Designation For Genentech’s Investigational Medicine ACE910 For People With Hemophilia A With Factor VIII Inhibitors
September 4, 2015
 · 
4 min read
Drug Development
Genentech Throws Cancers in a Basket to Detect Tumors at Their Genetic Roots
August 20, 2015
 · 
1 min read
Drug Development
Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors In People With A Specific Type Of Lung Cancer
August 17, 2015
 · 
4 min read
Drug Development
In A Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors In People With A Specific Type Of Bladder Cancer
July 13, 2015
 · 
5 min read
Policy
Exelixis Provides Update On Genentech’s Pending New Drug Application For Cobimetinib, An Exelixis-Discovered Compound
July 1, 2015
 · 
5 min read
Drug Development
Genentech’s Ocrelizumab Significantly Reduced Both Relapses And Disability Progression Versus Interferon Beta-1a (Rebif) In Two Phase III Studies In Multiple Sclerosis
June 30, 2015
 · 
5 min read
Business
Dream Foundation Announces Troy Cox, Genentech Senior Vice President And Officer, Has Been Appointed To The Board Of Directors
June 17, 2015
 · 
1 min read
Drug Development
Genentech’s Perjeta Regimen Helped People With HER2-Positive Early Breast Cancer Live Longer Without Their Disease Returning Or Getting Worse Compared To Herceptin And Chemotherapy
June 1, 2015
 · 
10 min read
Drug Development
Genentech’s Gazyva Extended The Time People With Refractory Indolent Non-Hodgkin’s Lymphoma Lived Without Their Disease Worsening
June 1, 2015
 · 
14 min read
Drug Development
Updated Data Showed Genentech’s Investigational Combination Of Cobimetinib And Zelboraf (Vemurafenib) Helps People With Advanced Melanoma Live For A Year Without Their Disease Worsening
June 1, 2015
 · 
9 min read
Load More